Chiron Real Estate Inc. (XRN) Names Charles P. Fitzgerald Chairman

Chiron Real Estate Inc. (XRN) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 2.01 Completion of Acquisition or Disposition of Assets. The Pinnacle North Bethesda On October 1, 2026, Chiron Real Estate Inc. (the " Company "), through one or more subsidiaries, closed on the acquisition of The Pinnacle North Bethesda (the “ Pinnacle ”), a senior housing

Chiron Real Estate (XRN) reported Q2 2026 net income of $63.3M ($4.78/diluted share), reversing a $0.8M loss from a year earlier. However, funds from operations (FFO) and core FFO declined. The company is focusing on senior housing, acquiring two luxury communities for $249M and reducing leverage to 39.9%. Despite some challenges in occupancy rates, management remains optimistic about long-term returns.

Chiron Real Estate (XRN) reported Q2 2026 results and discussed its shift toward senior housing. Net income attributable to common stockholders was $63.3 million, or $4.78 per diluted share. Core FFO was $1.04 per share. The company reported 96% occupancy at The Landing and 26% at The Riviera, plus $249 million inaugural senior housing acquisitions and a $100 million Series C preferred issuance.

Chiron Real Estate Inc. (XRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Chiron Real Estate Inc. Announces Second Quarter 2026 Financial Results –Advances Portfolio Repositioning Through SHOP Acquisitions and Legacy Asset Sales– –Expands Senior Housing Leadership Platform to Support Next Phase of Growth– Bethesda, MD – August 5, 2026 – (B

Chiron Real Estate Inc. (XRN) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-10.1 2 tm2619294d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Execution Copy Certain schedules or similar attachments to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. AGREEMENT OF PURCHASE AND SALE This Agreement of Purchase and Sale (this “ Agreement

Kyverna Therapeutics (KYTX) reported Phase 2 trial data showing sustained benefits of miv-cel in stiff person syndrome. Among 26 patients, walking performance improved by 49% and 92% remained free of chronic immunotherapies. No high-grade CRS or ICANS cases were reported. KYTX shares are trading at $5.97, down 1.16%.